This inventor holds 3 USPTO granted patents and 6 published patent applications. Top assignee: Scribe Therapeutics Inc.. Active years: 2024-2026.
Company Filing History:
Years Active: 2024-2026
Title: Suraj Makhija: Innovator in Genetic Engineering
Introduction
Suraj Makhija is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of genetic engineering, particularly in the development of innovative CRISPR systems. With a total of 3 patents to his name, Makhija is recognized for his groundbreaking work in modifying nucleic acids.
Latest Patents
Makhija's latest patents include engineered guide scaffolds, which provide engineered Class 2 Type V nucleases and guide RNAs useful for the editing of target nucleic acids. These patents also detail methods of making and using such variants to modify nucleic acids. Another notable patent is for engineered Class 2 Type V CRISPR systems, which similarly focus on the editing of target nucleic acids and the methods associated with these innovations.
Career Highlights
Suraj Makhija is currently employed at Scribe Therapeutics Inc., where he continues to push the boundaries of genetic research. His work has been instrumental in advancing the capabilities of CRISPR technology, making it more efficient and versatile for various applications.
Collaborations
Makhija collaborates with talented individuals in his field, including coworkers Isabel Colin and Sean Higgins. Their combined expertise fosters a dynamic environment for innovation and research.
Conclusion
Suraj Makhija stands out as a key figure in the realm of genetic engineering, with his patents paving the way for future advancements in CRISPR technology. His contributions are shaping the future of genetic research and applications.